Articles & Video
EU Pharmaceutical Law Forum 2020: Post-event Report
We review key session highlights from the virtual EU Pharmaceutical Law Forum.
COVID-19: Advice from the legal experts
We asked legal experts for their best tips and advice for pharmaceutical organisations during the COVID-19 pandemic.
State of the Industry — Critical Bio/Pharma Policy Updates for Compliance After COVID | Covington
Stefanie Doebler, Partner at Covington & Burling LLP, kicked off the Pharmaceutical Compliance Congress, with a State of the Industry focused on critical bio/pharma policy updates for compliance after COVID. Watch the full session here.
Practical Compliance Guidance: Key Learnings for DOJ Updates, OIG Fraud Alert and Open Payments Enforcement Action
In this compilation, Porzio Life Sciences provides recent updates from Porzio Compliance Digest highlighting the latest information on DOJ Updates, Fraud Alerts and Open Payments Enforcement Actions.
Next Gen Pharma Compliance: Data Analytics & Automation with Lextegrity
Parth Chanda, Founder & CEO of Lextegrity, discusses how off-the-shelf technology can help companies prevent and detect counterparty and spend risks using a mix of data analytics and automation.
Diversity & Inclusion in Compliance and Legal Teams
Watch a panel discussion on diversity and inclusion in compliance and legal teams.
Understand HCP Perspectives on Virtual/Hybrid/Live — Experiences and Preferences
Watch an on-demand panel discussion on understand HCP perspectives on Virtual/Hybrid/Live.
"Privacy continues to be an area of increasing focus and scrutiny" - Q&A with Epsilon Life Sciences
How in-house Legal and Compliance departments are evolving in 2020 to help address business challenges
Patient Services: Six strategies for optimizing cross-functional collaboration between compliance and access
Five industry experts from compliance and patient services explore how leading organizations promote better collaboration, communication, and patient outcomes in this whitepaper.
Life Sciences Survey: COVID-19 Impacts One Year On
Take part in our industry survey on the impacts of COVID-19 on the life sciences one year on to get exclusive early access to the final report.
From Enhanced Workflows To Advanced Analytics
Leveraging Transparency Reporting Data to Drive ROI
For years, IQVIA has rigorously documented best practices in how pharmaceutical companies, medical device manufacturers and other industry firms collect and report data pertaining to HCP engagements.
Late in 2020, IQVIA surveyed key stakeholders at biotech, pharmaceutical and medical device manufacturers. The survey revealed pain points facing compliance individuals, showing the importance of enterprise-wide, scalable solutions that improve reporting globally
Turn Insight into Action with Connected Intelligence
Leveraging compliance expertise, data, and automation to drive better outcomes.
Life sciences companies that position themselves to be early adopters of human data science will be ahead of the curve.
Well-managed compliance data collection and
reporting processes can mitigate compliance risk,
but there’s an even more compelling reason to invest
in policies and protocols to optimize the business
functions: Tools that support the relational analysis
of disparate data, position compliance departments
at the leading edge of a new landscape of ideas and
innovations in data utilization.
The best compliance management systems can yield
enterprise-wide benefits. You can unlock actionable
insights to inform future business decisions — creating
a positive feedback loop for meeting and improving
performance benchmarks. These intelligent solutions
don’t just facilitate compliance, they encourage
adoption, giving companies the tools needed to adapt
and improve business processes.
REPORT: Diversity, Equity and Inclusion in the Life Sciences 2021
Explore the Diversity, Equity and Inclusion in the Life Sciences 2021 report based on an exclusive study of 483 industry professionals.
Top 5 Takeaways from the 2020 Compliance Congress for Specialty Products
On September 21st - 24th, 2020, Informa Connect-CBI hosted its 6th Annual Compliance Congress for Specialty Products. The Congress catered to the unique Legal and Compliance challenges for specialty pharmaceutical companies focused on rare, ultra-rare and orphan diseases. Helio Health Group identified five key takeaways from the Congress that every Compliance Officer should be considering.
COVID-19 and Compliance Teams in Life Science Industry: 2021 Survey Report
After the tumultuous year that 2020 was,
we invited responses for our “COVID-19
and Compliance Teams in Life
Sciences Industry” survey to gauge
the impact of the COVID pandemic on
compliance departments across life
The survey was divided to record
responses with respect to compliance
teams size, budgets, use of counsel,
mode of monitoring and training.
SURVEY: Diversity, Equity and Inclusion in the Life Sciences 2021
Complete our survey on Diversity, Equity and Inclusion in the Life Sciences 2021 to get exclusive early access to the final report.
HCP Promotional Engagement Benchmarks Report — Special Edition: Pre-Pandemic Snapshot and COVID-19 Impact Evaluation
This year’s annual analysis of life sciences promotional speaker programming
data is quite different from previous years’ snapshots. The COVID-19 pandemic
has upended industries around the world; life sciences is no exception.
2020 U.S. Trends in Transparency Reporting
As befits a fast-paced, dynamic industry, the life sciences regulatory landscape is perpetually in flux. For the past 11 years, IQVIA has rigorously documented best practices in how pharmaceutical companies, medical device manufacturers and other industry firms collect and report data pertaining to HCP engagements.
Independent Charitable Copay Foundation Donations: What to Consider and Steps to Take Before Donating and What Recent Court Challenges Might Mean for Industry
From our recent Patient Support Services 2020, Katherine Chaurette of Blueprint Medicines and Rahul Khara of Acceleron Pharma Inc. dive into an overview and brief background of the OIG Guidance, manufacturer and foundation enforcement actions, compliance considerations and so much more in this presentation on Independent Charitable Copay Foundation Donations.